About Us
Company Overview
Company History
Leadership Team
Partner
Portfolio Advisory Board
Media Center
Our Science
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications
Product
HuaTangNing(华堂宁®)
Media
Company News
Media Releases
Video
Investor Relations
Investor Center
Corporate Governance
Financial Report
Announcements and Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock Information (2552.HK)
Corporate Communications
Careers
Company Culture
Join Us
Contact Us
中
中
中

Our Science

 >  Our Science
 >  Pipeline
Science & Innovation
Pipeline
Dorzagliatin
mGluR5
Poster and Presentation
Peer Reviewed Publications

Pipeline

Product and Pipeline
Indication
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
Dorzagliatin
T2D - Drug Naïve
T2D - Metformin Tolerated
RWE study for Diabetes Remission
MODY-2
Diabetes prevention IGT2NGT
Frailty
Early AD
CFRD
Dorzagliatin and Metformin FDC
T2D
2nd Generation GKA
Metabolic Disease
Dorzagliatin add on to GLP1RAs
T2D and Obesity
Dorzagliatin + small molecule GLP-1
T2D and Obesity
Dorzagliatin + Empagliflozin
DKD
Dorzagliatin + Sitagliptin
T2D
Dorzagliatin add on to Insulin
Insulin sparing in T2D
mGLUR5 NAM
PD-LID
Drug Addiction
GK NAM
Metabolic Disease
Dorzagliatin
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
T2D - Drug Naïve
T2D - Metformin Tolerated
RWE study for Diabetes Remission
MODY-2
Diabetes prevention IGT2NGT
Frailty
Early AD
CFRD
Dorzagliatin and Metformin FDC
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
T2D
2nd Generation GKA
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
Metabolic Disease
Dorzagliatin add on to GLP1RAs
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
T2D and Obesity
Dorzagliatin + small molecule GLP-1
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
T2D and Obesity
Dorzagliatin + Empagliflozin
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
DKD
Dorzagliatin + Sitagliptin
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
T2D
Dorzagliatin add on to Insulin
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
Insulin sparing in T2D
mGLUR5 NAM
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
PD-LID
Drug Addiction
GK NAM
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
Metabolic Disease
About Us
Company Overview
Company History
Leadership Team
Portfolio Advisory Board
Partner
Media center
Research & Development
Inovation
Pipeline
Dorzagliatin
mGluR5
Company Publications
Peer Reviewed Publications
Investor Relations
Corporate Governance
Financial Report
Announcements & Circulars
Listing Documents
Investor Presentation
IR Contact
Investor Calendar
Stock information
Media
Company News
Media Releases
Video
Careers
Culture
Join Us
Product
HuaTangNing(华堂宁®)
Focus Us
Copyright © 2025  Hua Medicine (Shanghai) Ltd.    互联网药品信息服务资格证书编号: （沪）-非经营-2022-0079
沪ICP备14036654号-1  beiantubiao.png 沪公网安备 31011502013809号  Privacy Statement  Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
Accept
x